ALDX
Aldeyra Therapeutics Inc (ALDX)
Healthcare • NASDAQ • $1.730.00%
- Symbol
- ALDX
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $1.73
- Daily Change
- 0.00%
- Market Cap
- $104.36M
- Trailing P/E
- N/A
- Forward P/E
- -6.72
- 52W High
- $6.18
- 52W Low
- $1.07
- Analyst Target
- $7.60
- Dividend Yield
- N/A
- Beta
- N/A
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associate…
Company websiteResearch ALDX on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.